Hims & Hers Scales Technology-Enabled, Vertically Integrated Care
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, operates an integrated, proprietary technology platform that manages the full journey from customer discovery to ongoing clinical management. The platform connects consumers to a distributed provider network, a proprietary electronic medical record, digital prescribing, and in-house mail-order pharmacies, enabling subscription-based care across categories […]
GLP-1 drugs found to reduce mortality from colon cancer by over half (15.5% vs 37.1%), with effects especially strong for patients with BMI over 35.
submitted by /u/Lisei1128 [link] [comments]
Ozempic Weight Loss Ads; New Dietary Guidelines; More Type 1.5 Diabetes Diagnoses
(MedPage Today) — Due to sponsored search results — a form of online advertising — the Ozempic formulation of semaglutide appears in Google searches for weight loss, despite not being FDA-approved for this indication. (NPR)
New analyses…
GLP-1 drugs linked to improved survival in colon cancer patients
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists – the class of drugs behind Ozempic, Wegovy and Mounjaro, for example – may do more than regulate blood sugar and weight.
Thin Is Back With a Vengeance
Did people really mean it when they said being fat is fine, and they don’t want to be thin? GLP-1 drugs may be changing this outlook.
White House denies post-election pivot as Trump prepares new affordability push
In the days following last Tuesday’s sweeping Democratic victories, Trump administration officials fanned out across news outlets to highlight the administration’s focus on affordability, assuring Americans that prices have fallen under President Donald Trump. The president himself reiterated his claim—made many times before—that grocery prices are “way down.” Critics say that overall, prices largely have […]
Investigational GLP-1-Based Drug Hits MASH Resolution Mark, Misses Fibrosis Target
(MedPage Today) — WASHINGTON — Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening of fibrosis, but did not improve…
Price Cuts Help More Americans Start Weight-loss Drugs but Maybe Not Stay on Them
A Trump administration deal to cut prices for popular weight-loss drugs like Wegovy and Zepbound will allow millions more Americans to give them a try, but the cost may… Reuters Health Information
GLP-1 drugs linked to dramatically lower death rates in colon cancer patients
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may do more than regulate blood sugar and weight. In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that […]
Readers respond: Expand access to obesity medicine
A recent Oregonian/OregonLive article highlights an important step toward improving access to safe, effective GLP-1 medications, (“Ozempic and Wegovy will be sold for half price at Costco,” Oct. 8).